Peptidify
← Back to the journal
HUMAN TRIALSeptember 19, 2026 · 6 min read

Retatrutide's phase 2 numbers still look unreal. They aren't.

The triple agonist produced a 24% mean weight loss in a 48-week trial — a result no approved drug has matched since. What the data actually says, and what it doesn't.

The number everyone quotes

In the phase 2 dose-finding trial published in the New England Journal of Medicine (Jastreboff et al., 2023), adults with obesity received retatrutide — a single peptide engineered to activate three receptors at once: GLP-1, GIP and glucagon. At the highest dose (12 mg), mean body weight fell 24.2% over 48 weeks, versus 2.1% on placebo. Roughly one in four participants on the top dose lost 30% or more of their body weight.

Why the triple mechanism matters

Semaglutide works one receptor. Tirzepatide works two. Retatrutide adds glucagon receptor activation on top of GLP-1 and GIP — and glucagon is the interesting bet. It raises energy expenditure and shifts hepatic fat metabolism, which is the mechanistic argument for why the weight loss exceeds either predecessor. The trade-off is exactly what you would predict from stimulating a catecholamine-adjacent pathway: dose-dependent heart-rate increases of 2 to 4 beats per minute, and a tolerability profile that demands slow titration.

The safety fine print

Gastrointestinal events dominated, as they do across the entire incretin class: nausea, vomiting and diarrhea in a clear dose relationship, mostly transient. Two signals deserve attention rather than dismissal. First, the heart-rate increase was consistent across doses and did not fully resolve during the trial. Second, 48 weeks is simply not long enough to judge cardiovascular outcomes one way or the other — that is what the phase 3 program exists to determine.

Where things stand now

The first phase 3 readouts reported in December 2025 pushed the number higher: 28.7% mean weight loss at 68 weeks in the TRIUMPH-4 trial. For context, that approaches the territory of bariatric surgery, which historically produced 25 to 30% loss in the same class of patients. The four-trial TRIUMPH program has now completed, and regulatory filings are the next gate — approval would turn retatrutide from the most promising molecule in the class into the most potent approved one.

What this means for the codex entry

Retatrutide's grading stays the point: regulatory status is clinical-trial (not yet approved as of this writing), while human evidence is genuinely strong — multiple randomized, controlled, published trials with thousands of participants. The error to avoid is the mirror image of the usual one: dismissing approved-drug-tier data because the molecule is discussed in gray-market peptide spaces. The evidence here is the strongest in the entire metabolic section of the codex.

The takeaway

  • 01Phase 2: −24.2% mean weight loss at 48 weeks on 12 mg (NEJM, 2023); phase 3 TRIUMPH-4 readout: −28.7% at 68 weeks.
  • 02The glucagon receptor component is the differentiator — and the source of the heart-rate signal.
  • 03GI side effects are class-typical and dose-dependent; long-term cardiovascular outcomes are still unknown.
  • 04Evidence strength here is the opposite of the typical gray-market peptide profile: robust, published, replicated.

Verdict — WATCH

Strongest efficacy signal in the obesity pipeline. The open questions are cardiovascular long-term data and regulatory timing, not whether the molecule works.

References

  1. Jastreboff AM, et al. Retatrutide Phase 2 Obesity Trial. New England Journal of Medicine, 2023.
  2. Eli Lilly. TRIUMPH-4 phase 3 topline results, announced December 2025.
  3. Retatrutide monograph — Peptidify codex, last verified 2026-09.